OK138太阳集团 (OK138 Sun Group) is a pharmaceutical company focused on developing and producing quality medicines for public health. The company has received recognition, including the 27th Listed Company Golden Bull Award for its innovative contributions and a top-tier A-level rating for information disclosure from the Shanghai Stock Exchange. Their recent achievements include the approval of their chemical raw material drug Gatifloxacin for market and the initiation of clinical trials for a new anti-tumor drug, JJH201601 liposome.